Esperion Therapeutics (NASDAQ:ESPR) was upgraded by BidaskClub from a "hold" rating to a "buy" rating in a research report issued to clients and investors on Thursday, BidAskClub reports.
Several other analysts have also recently commented on ESPR. Needham & Company LLC restated a "buy" rating on shares of Esperion Therapeutics in a report on Thursday, May 7th. Zacks Investment Research raised Esperion Therapeutics from a "hold" rating to a "buy" rating and set a $40.00 price target on the stock in a research note on Thursday, March 26th. Northland Securities initiated coverage on Esperion Therapeutics in a research note on Tuesday, June 23rd. They set a "hold" rating and a $42.00 price target on the stock. Jefferies Financial Group cut their price target on Esperion Therapeutics from $85.00 to $70.00 and set a "buy" rating on the stock in a research note on Thursday, May 7th. Finally, Citigroup upped their price target on Esperion Therapeutics from $46.00 to $56.00 and gave the company a "buy" rating in a research note on Thursday, May 7th. Four investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company's stock. The company has a consensus rating of "Buy" and an average price target of $78.50.
Shares of ESPR stock opened at $51.12 on Thursday. The stock's fifty day moving average is $44.51 and its 200-day moving average is $48.13. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.33 and a current ratio of 2.35. The stock has a market capitalization of $1.32 billion, a PE ratio of -5.31 and a beta of 2.16. Esperion Therapeutics has a 52 week low of $24.82 and a 52 week high of $76.98.
Esperion Therapeutics (NASDAQ:ESPR) last announced its earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($2.84) EPS for the quarter, topping the consensus estimate of ($3.14) by $0.30. The company had revenue of $1.80 million for the quarter, compared to analysts' expectations of $0.39 million. Esperion Therapeutics had a negative return on equity of 627.38% and a negative net margin of 5,492.02%. The business's revenue for the quarter was down 98.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.07 earnings per share. As a group, analysts forecast that Esperion Therapeutics will post -4.95 earnings per share for the current fiscal year.
Large investors have recently added to or reduced their stakes in the business. Acadian Asset Management LLC acquired a new position in Esperion Therapeutics in the first quarter valued at about $43,000. PNC Financial Services Group Inc. lifted its stake in Esperion Therapeutics by 32,833.3% in the first quarter. PNC Financial Services Group Inc. now owns 1,976 shares of the biopharmaceutical company's stock valued at $62,000 after buying an additional 1,970 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Esperion Therapeutics by 59.8% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,159 shares of the biopharmaceutical company's stock valued at $68,000 after buying an additional 808 shares during the period. Ladenburg Thalmann Financial Services Inc. lifted its stake in Esperion Therapeutics by 68.1% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,348 shares of the biopharmaceutical company's stock valued at $80,000 after buying an additional 546 shares during the period. Finally, Ancora Advisors LLC acquired a new position in Esperion Therapeutics in the fourth quarter valued at about $134,000.
About Esperion Therapeutics
Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.
Featured Article: Economic Bubble
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
10 Buy and Hold Stocks to Add to Your Portfolio
“Set it and forget it” are words many investors don’t want to hear. Even the most venerable brokerage houses are encouraging their clients to actively trade so they can beat the market. Buy and hold is a relic, they say. It doesn’t reflect the reality of today.
In other words, “this time it’s different”.
As the ongoing volatility in the market shows you, it’s not different. It’s not even close to being different. The simple fact is that many active traders lose money by being too aggressive and too active for their own good.
And while it’s true that the market won’t always be this choppy, and certain stocks may be a great buy in months to come, right now investors are looking for safe harbors. One of the safest ways to invest is to find stocks that you can feel comfortable holding on to even in the worst of times. Frequently that can be because the stocks offer an attractive dividend. But sometimes, it’s also because they are in a market that is always in demand.
But that doesn’t mean you have to limit yourself to defensive stocks. You can find some quality buy-and-hold stocks that offer some attractive growth prospects.
View the "10 Buy and Hold Stocks to Add to Your Portfolio".